NKE heads into the back half of 2026 with short interest at a multi-month high, options positioning tilting more defensive, and a street divided sharply on whether the bottom is in.
The most striking data point right now is the speed of the short rebuild. Short interest climbed to nearly 5.9% of the free float — up 56% over the past month. That move, from around 44 million shares short in mid-June to over 70 million today, represents one of the sharpest build-ups in borrowed positions the stock has seen in recent history. The week itself was relatively quiet, with SI essentially flat, suggesting the bulk of the positioning is already in place rather than actively expanding. Importantly, the borrow market remains wide open: availability is running at over 1,000%, meaning there is roughly ten times as much stock available to lend as there is currently borrowed — borrow is not a constraint for new shorts entering the trade. Cost to borrow, at 0.43%, is low by any measure, edging up roughly 6% on the week but nowhere near levels that would signal a squeeze. That combination — elevated short interest, loose borrow, abundant availability — points to a market that is structurally bearish but not under any technical pressure.
Options positioning has also grown more cautious, though not yet extreme. The put/call ratio moved to 0.79, above its 20-day average of 0.76 by about 1.2 standard deviations. That puts options sentiment modestly defensive — notable given the stock's 1.2% dip on Tuesday to close at $42.96 — but well short of the year's most hedged reading of 0.95. The directional shift in PCR over the past two weeks is clearer than the absolute level: the ratio has ticked higher almost every session since mid-July, consistent with investors adding downside cover ahead of the next earnings event in early October.
The Street is split in a way that reveals genuine uncertainty about the recovery timeline. Bulls, including Jefferies and Bernstein, hold buy-equivalent ratings but have been cutting targets — Jefferies moved its target from $90 to $75 on July 1, Bernstein from $80 to $72 — a pattern of maintained conviction paired with lowered near-term expectations. On the other side, Citi and UBS sit at neutral, with targets of $45 and $48 respectively, close to where the stock is actually trading. The bear case from BNP Paribas, with a $23 target, reflects a structural concern: heavy outsourcing risk, over-reliance on footwear, and deteriorating momentum in China and EMEA. The bull case centres on margin recovery and long-run brand equity, with a $65 upside scenario in view. Valuation has re-rated meaningfully — the P/E multiple is around 21x, down sharply from above 40x a month ago, while price-to-book has contracted nearly 9% in 30 days. The 90-day EPS momentum factor score ranks in the 96th percentile, and the EPS surprise score sits at the 97th — the company has been beating estimates, even as those estimates have come down.
The insider picture from earlier in the year is worth noting. In early April, CEO Elliott Hill bought nearly $1 million of stock at roughly $42.27, and Apple lead director Tim Cook added $1.06 million at $42.43. Multiple independent directors also bought in that window. Those purchases came at prices almost identical to where NKE trades today — making the current level a clear line in the sand from management's perspective. More recent activity has been modest selling from an EVP and COO in June, but at higher prices ($44-$46 range), which reads as routine rather than a directional signal.
Closely correlated peer UAA surged 11.5% on the week, while ONON edged lower by 1.3% — the footwear space is not moving as a bloc. NKE's flat week (+0.2%) puts it in the middle of the peer range, a small reprieve from the 5% monthly slide. The divergence between UAA's rebound and NKE's stagnation reinforces the narrative that NKE's issues are company-specific rather than category-wide.
The October 1 earnings date is the next meaningful catalyst. With short interest now near the highest level seen in recent months, borrow still cheap, and options traders quietly layering on protection, the question heading into that print is whether the financial health improvements signalled by the quality metrics — rising ROA, a better Piotroski score — translate into evidence of actual revenue recovery, particularly in China and EMEA.
See the live data behind this article on ORTEX.
Open NKE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
